Lin Zhang

US Patent:

6383743, May 7, 2002

Filed:

Jun 30, 1998

Appl. No.:

09/107228

Inventors:

Kenneth W. Kinzler - Bel Air MD
Bert Vogelstein - Baltimore MD
Victor E. Velculescu - Baltimore MD
Lin Zhang - Baltimore MD

Assignee:

The John Hopkins University School of Medicine - Baltimore MD

International Classification:

C12Q 168

US Classification:

435 6, 435196, 536 231, 702 19

Abstract:

Serial analysis of gene expression, SAGE, a method for the rapid quantitative and qualitative analysis of transcripts is provided. Short defined sequence tags corresponding to expressed genes are isolated and analyzed. Sequencing of over 1,000 defined tags in a short period of time (e. g. , hours) reveals a gene expression pattern characteristic of the function of a cell or tissue. Moreover, SAGE is useful as a gene discovery tool for the identification and isolation of novel sequence tags corresponding to novel transcripts and genes.

US Patent:

6746845, Jun 8, 2004

Filed:

Mar 14, 2002

Appl. No.:

10/096596

Inventors:

Kenneth W. Kinzler - Bel Air MD
Bert Vogelstein - Baltimore MD
Victor E. Velculescu - Baltimore MD
Lin Zhang - Baltimore MD

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 168

US Classification:

435 6, 435 911, 435 915, 536 231, 536 242

Abstract:

Serial analysis of gene expression, SAGE, a method for the rapid quantitative and qualitative analysis of transcripts is provided. Short defined sequence tags corresponding to expressed genes are isolated and analyzed. Sequencing of over 1,000 defined tags in a short period of time (e. g. , hours) reveals a gene expression pattern characteristic of the function of a cell or tissue. Moreover, SAGE is useful as a gene discovery tool for the identification and isolation of novel sequence tags corresponding to novel transcripts and genes.

US Patent:

7014866, Mar 21, 2006

Filed:

May 2, 2002

Appl. No.:

10/138071

Inventors:

Martin Howard Infeld - Upper Montclair NJ, US
Wantanee Phuapradit - Clifton NJ, US
Navnit Hargovindas Shah - Clifton NJ, US
Lin Zhang - Piscataway NJ, US

Assignee:

Hoffmann-La Roche Inc. - Nutley NJ

International Classification:

A61K 9/20

US Classification:

424464, 424451, 424470, 514772, 5147723

Abstract:

A solid unit oral pharmaceutical dosage form of amorphous nelfinavir mesylate is provided comprising amorphous nelfinavir mesylate in an amount of from about 400 mg to about 700 mg calculated as nelfinavir base, and a pharmaceutically acceptable water soluble, non-ionic synthetic block copolymer of ethylene oxide and propylene oxide, the copolymer having a melting point of at least about 45 C. and an HLB value at 25 C. of from about 18 to about 29, wherein the copolymer is present from about 40% to about 65% by weight of the nelfinavir mesylate. A hot melt granulation process for making the dosage form is provided.

US Patent:

8455176, Jun 4, 2013

Filed:

Nov 12, 2008

Appl. No.:

12/269072

Inventors:

Francis Houlihan - Millington NJ, US
Lin Zhang - Edison NJ, US
Alberto Dioses - Doylestown PA, US
Meng Li - Edison NJ, US

Assignee:

AZ Electronic Materials USA Corp. - Somerville NJ

International Classification:

G03F 7/031
G03F 7/039
G03F 7/095
G03F 7/38
G03F 7/40
G03F 7/30

US Classification:

4302881, 4302701, 430326, 430311, 430330, 430927

Abstract:

Developable bottom antireflective coating compositions are provided.

US Patent:

20050009811, Jan 13, 2005

Filed:

Jul 8, 2004

Appl. No.:

10/886765

Inventors:

Antonio Albano - Clifton NJ, US
Martin Infeld - Upper Montclair NJ, US
Wantanee Phuapradit - Montville NJ, US
Navnit Shah - Clifton NJ, US
Lin Zhang - Bloomfield NJ, US

International Classification:

A61K031/551

US Classification:

514220000

Abstract:

A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight.

US Patent:

20080107725, May 8, 2008

Filed:

Oct 2, 2007

Appl. No.:

11/866102

Inventors:

Antonio Albano - Clifton NJ, US
Wantanee Phuapradit - Montville NJ, US
Navnit Shah - Clifton NJ, US
Zhongshui Yu - Bridgewater NJ, US
Lin Zhang - Nutley NJ, US

International Classification:

A61K 9/48
A61K 31/4965

US Classification:

424451000, 514255060

Abstract:

The present invention provides novel pharmaceutical solid dosage forms for oral administration comprising a therapeutically effective amount of an unstable crystalline form or an amorphous form of a therapeutically effective compound micro-embedded into an ionic water-insoluble polymer. The therapeutically effective compounds, which have a tendency to gel, are micro-embedded into an ionic water-insoluble polymer matrix to provide a dosage form having rapid, reproducible, and complete dissolution profiles. These novel solid pharmaceutical dosage forms are useful in the treatment or control of a number of diseases. The present invention also provides a method for treating a disease comprising administering to a subject, in need thereof, a therapeutically effective amount of the novel solid pharmaceutical dosage form. The present invention further provides a method for preparing the pharmaceutical dosage forms.

US Patent:

20090054481, Feb 26, 2009

Filed:

Oct 31, 2008

Appl. No.:

12/262607

Inventors:

Antonio A. Albano - Clifton NJ, US
Martin Howard Infeld - Upper Montclair NJ, US
Wantanee Phuapradit - Montville NJ, US
Navnit Hargovindas Shah - Clifton NJ, US
Lin Zhang - Bloomfield NJ, US

International Classification:

A61K 31/4725

US Classification:

514307

Abstract:

A solid unit oral pharmaceutical dosage form of saquinavir mesylate is provided comprising micronized saquinavir mesylate in an amount of from 250 mg to 800 mg calculated as free base, and a pharmaceutically acceptable binder, disintegrant, and water soluble carrier. A solid unit dosage form of saquinavir mesylate is provided comprising from 60% to 80% micronized saquinavir mesylate based on the mesylate salt, 4% to 8% water soluble binder, a disintegrant and a carrier, wherein each percentage is of the kernel weight.

US Patent:

20110076587, Mar 31, 2011

Filed:

Sep 28, 2010

Appl. No.:

12/892791

Inventors:

CONGHUA WANG - West Windsor NJ, US
LIN ZHANG - Edison NJ, US

Assignee:

TREADSTONE TECHNOLOGIES, INC. - Princeton NJ

International Classification:

H01M 8/24
B22F 7/00
C23C 4/10
B05D 3/10
B32B 5/16
H01M 8/10

US Classification:

429465, 428552, 427453, 427448, 216 13, 428328

Abstract:

A method to use a novel structured metal-ceramic composite powder to improve the surface electrical conductivity of corrosion resistant metal substrates by thermal spraying the structured powder onto a surface of a metallic substrate is disclosed. The structured powder has a metal core and is wholly or partially surrounded by an electrically conductive ceramic material such as a metal nitride material. The metal cores may have the ceramic material formed on them prior to a thermal spraying process performed in an inert atmosphere, or the thermal spraying may be performed in a reactive atmosphere such that the ceramic coating forms on the cores during the thermal spraying process and/or after deposition. The metal cores will bond conductive ceramic material onto the surface of the substrate through the thermal spray process.